Intravitreal injection of bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for diabetic macular edema and proliferative diabetic retinopathy.
Vascular endothelial growth factor (VEGF) is a major driving force in the development of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Intravitreal injection of the anti-VEFG medication bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for DME and PDR.
The reference Avastin was approved to treat cancer, as was its biosimilar (Mvasi), but its off-label use to treat diabetic retinopathy remains popular and widespread around the world, especially in low-income countries, given its lower cost, perceived effectiveness, and comparable safety profile.
Writing for the Pan-American Collaborative Retina Study Group (PACORES), J. Fernando Arevalo, MD, and T.Y. Alvin Liu, MD, reviewed 5 years of experience using intravitreal bevacizumab for diabetic retinopathy in Latin America and Spain, and conclude that it is an important tool in the armamentarium for treating the complications of diabetic retinopathy.
The researchers add that intravitreal bevacizumab can also be used as a preoperative, adjuvant therapy before vitrectromy for proliferative diabetic retinopathy. Their study provides one of the longest-term follow-up data sets on the efficacy of the anti-VEGF treatments in DME. The review is published in the December 2017 issue of Asia-Pacific Journal of Ophthalmology (Philadelphia).
Their study enrolled 201 patients (296 eyes) with center-involving DME and vision loss who were treated monthly with 1.25 mg of intravitreal bevacizumab until edema was stabilized, then returned to clinic and treated on an as-needed regimen, based on best corrected visual acuity (BCVA) and optical coherence tomography (OCT). The main outcome measures were changes in BCVA and central macular thickness (CMT) at the 60-month follow-up visit.
The group’s data on preoperative intravitreal bevacizumab suggest that it is beneficial before vitrectomy for PDR, as it tends to decrease intraoperative bleeding, facilitate intraoperative fibroproliferative membrane dissection, and decrease postoperative bleeding. The researchers believe intravitreal bevacizumab before vitrectomy is safe, especially with careful planning and patient selection.
“Based on our experience, we recognize intravitreal bevacizumab to be an important tool in our armamentarium for treating the complications of diabetic retinopathy,” they conclude. “For center-involving DME, our real-world data suggest that there is a roughly 70% chance of stabilized or improved vision with intravitreal bevacizumab treatments over a time course of 5 years,” they write, adding that for PDR, intravitreal bevacizumab is a good adjuvant therapy for patients who have already received prior panretinal photocoagulation treatment. Finally, they conclude that preoperative intravitreal bevacizumab before vitrectromy is safe, with a low incidence of development or progression of tractional retinal detachment.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.